Gamunex-C can be administered either as an intravenous (IV) infusion by a healthcare professional or, for Primary Humoral Immunodeficiency, as a subcutaneous (SC) infusion by trained patients or caregivers at home.
Intravenous (IV) Administration (for PIDD, ITP, and CIDP):
- Preparation: Gamunex-C is supplied as a 10% liquid solution, ready to use. Visually inspect the solution for particulate matter and discoloration prior to administration; do not use if it is turbid. Allow the solution to reach ambient room temperature before infusion. Do not freeze the product. Do not dilute Gamunex-C with other intravenous fluids or medications; if dilution is required (rarely, for very small pediatric patients), only 5% Dextrose in Water (D5W) should be used.
- Procedure: Administered directly into a vein using an infusion pump.
- Infusion Rate: Infusion should start at a slow initial rate (e.g., 1 mg/kg/min or 0.01 mL/kg/min for 30 minutes). If well-tolerated, the rate may be gradually increased (e.g., up to 8 mg/kg/min or 0.08 mL/kg/min). For patients at risk of renal dysfunction or thrombosis, administer Gamunex-C at the minimum dose and infusion rate practicable.
- Dedicated Line: Use a separate IV line for Gamunex-C infusion. The line can be flushed with D5W or 0.9% Sodium Chloride for Injection.
Subcutaneous (SC) Administration (for PIDD only):
- Preparation: Also a ready-to-use 10% liquid solution. Allow to reach ambient room temperature before use.
- Procedure: Administered using a dedicated infusion pump into the subcutaneous tissue, typically at multiple sites (e.g., abdomen, thighs, upper arms). Patients or caregivers must receive comprehensive training from a healthcare professional on proper aseptic technique, equipment use, and site management for home infusions.
- Frequency: Usually administered weekly, but dosing frequency can be individualized.
- Site Rotation: Infusion sites must be rotated with each infusion to minimize local adverse reactions. Infusion sites should be at least 2 inches (5 cm) apart.
- Not for ITP or CIDP: SC administration is not approved for ITP or CIDP due to the potential risk of hematoma formation in ITP and the need for rapid systemic levels in CIDP often best achieved via IV.
The specific dose, frequency, and route of administration are determined by the healthcare provider based on the individual patient’s condition, body weight, and response to treatment.
Gamunex-C provides therapeutic benefits through two primary mechanisms, depending on the condition being treated:
- Passive Immunization: In patients with Primary Humoral Immunodeficiency (PIDD), Gamunex-C directly replaces deficient or absent IgG antibodies. These antibodies, obtained from a large pool of healthy donors, offer a wide range of IgG specificities against various bacterial, viral, parasitic, and mycoplasmal agents and their toxins. By providing these antibodies, Gamunex-C enhances the patient’s immune defense, enabling them to neutralize pathogens and reduce the incidence and severity of infections.
- Immune Modulation: In autoimmune and inflammatory conditions like Idiopathic Thrombocytopenic Purpura (ITP) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Gamunex-C works through complex immunomodulatory effects. While the precise mechanisms are not fully elucidated, they are thought to involve:
- Fc Receptor Blockade: The Fc (crystallizable) portion of the infused IgG can saturate Fc receptors on immune cells (e.g., macrophages, phagocytes). This prevents these cells from binding to and destroying autoantibody-coated platelets (in ITP) or contributing to nerve damage (in CIDP).
- Neutralization of Autoantibodies: The diverse pool of antibodies in Gamunex-C may contain anti-idiotypic antibodies that can bind to and neutralize disease-causing autoantibodies.
- Modulation of Cytokine and Chemokine Production: It can influence the production and activity of various pro-inflammatory and anti-inflammatory mediators, helping to restore immune balance and disrupt inflammatory cascades.
- Complement System Inhibition: Gamunex-C can interfere with the activation of the complement cascade, which is involved in immune-mediated inflammation and tissue damage.
- Regulation of B and T Cells: It may affect the function, proliferation, and differentiation of B and T lymphocytes, crucial for adaptive immunity and autoimmune processes.
The route of administration (IV vs. SC) influences the pharmacokinetic profile, with IV administration leading to rapid high peak concentrations and SC administration resulting in more stable, sustained IgG levels.
Gamunex-C can cause side effects, which can vary in incidence and severity depending on the route of administration, indication, and individual patient factors. Most common reactions are mild and temporary, but serious adverse events can occur.
Common Side Effects:
- With IV Administration: Headache, fever, chills (rigors), fatigue, nausea, vomiting, dizziness, abdominal pain, muscle pain (myalgia), back pain, chest discomfort, cough, rash, pruritus (itching), flushing, blood pressure changes (increase or decrease). These are often infusion-related and may be managed by adjusting the infusion rate or with pre-medication.
- With SC Administration (primarily for PIDD): Local infusion site reactions are very common, including pain, swelling, redness (erythema), itching, bruising, and warmth at the injection site. These reactions are usually mild, localized, and resolve within a day. Systemic common side effects (e.g., headache, fatigue, nausea) tend to be less frequent or less severe compared to IV administration.
- Other Common (across both routes): Upper respiratory tract infection, pharyngitis, sinusitis.
Serious Side Effects (can occur with both IV and SC administration, but some more common with IV):
- Severe Hypersensitivity/Anaphylaxis: Rare but life-threatening allergic reactions, including severe hives, swelling of the face, throat, or tongue, severe difficulty breathing, wheezing, profound dizziness, chest pain, or loss of consciousness. The risk is significantly higher in patients with total IgA deficiency who have antibodies to IgA.
- Acute Renal Dysfunction/Failure: Risk is elevated in predisposed patients (pre-existing kidney disease, diabetes, dehydration, advanced age, certain concomitant medications). Symptoms may include decreased urination or swelling. Gamunex-C is sucrose-free, which may reduce this risk compared to sucrose-containing IVIG products.
- Thromboembolic Events (Blood Clots): Blood clots in the heart (myocardial infarction), brain (stroke), lungs (pulmonary embolism), or deep veins (DVT) can occur. Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, or a history of clots.
- Aseptic Meningitis Syndrome (AMS): A rare, non-infectious inflammation of the meninges, characterized by severe headache, stiff neck, fever, photophobia (light sensitivity), nausea, and vomiting.
- Hemolysis: Destruction of red blood cells, which can lead to anemia. Symptoms include dark urine, pale skin, or yellowing of skin/eyes.
- Transfusion-Related Acute Lung Injury (TRALI): A rare but severe lung complication with sudden onset of shortness of breath and hypoxemia.
- Volume Overload: Can occur, particularly with rapid or high-volume infusions in patients with underlying cardiac or renal compromise.
Any new, unusual, or worsening symptoms, especially severe ones, should be reported to the healthcare provider immediately.
Gamunex-C carries several important warnings and precautions that healthcare providers and patients must observe for safe use.
- Boxed Warning: Thrombosis, Renal Dysfunction, and Acute Renal Failure:
- Thrombosis (Blood Clots): Thrombosis may occur with immune globulin products, including Gamunex-C. Risk factors include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Administer Gamunex-C at the minimum dose and infusion rate practicable for patients at risk. Ensure adequate hydration before administration.
- Renal Dysfunction and Acute Renal Failure: Acute renal dysfunction and failure can occur, particularly in predisposed patients (those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs). Gamunex-C is sucrose-free, which reduces this risk compared to sucrose-containing IVIG products, but adequate hydration and monitoring of renal function (BUN/creatinine) are still crucial.
- Hypersensitivity/Anaphylaxis: Gamunex-C is contraindicated in individuals with a history of anaphylactic or severe systemic reactions to human immune globulin. It is also contraindicated in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity reaction due to the increased risk of severe anaphylaxis. Emergency medical support must be immediately available during administration.
- Aseptic Meningitis Syndrome (AMS): Patients should be monitored for signs and symptoms of AMS.
- Hemolysis: Gamunex-C contains blood group antibodies and can cause hemolysis. Patients should be closely monitored for clinical signs and symptoms of hemolysis and hemolytic anemia, especially those with non-O blood group or pre-existing anemia.
- Transfusion-Related Acute Lung Injury (TRALI): Monitor patients for pulmonary adverse reactions.
- Volume Overload: Can occur, particularly with rapid or high-volume infusions in patients with underlying cardiac or renal compromise.
- Transmission of Infectious Agents: Because Gamunex-C is made from human plasma, it may carry a risk of transmitting infectious agents (e.g., viruses, the variant Creutzfeldt-Jakob disease [vCJD] agent, and theoretically, the Creutzfeldt-Jakob disease [CJD] agent), despite extensive donor screening and viral inactivation/removal processes.
- Interference with Live Virus Vaccines: Gamunex-C can interfere with the development of immunity to live attenuated virus vaccines.
- Interference with Laboratory Tests: Passively transferred antibodies can lead to false-positive serological test results or interfere with certain laboratory assays.
- Hyperproteinemia, Increased Serum Viscosity, and Pseudohyponatremia: These can occur. Patients should be monitored for these changes, and pseudohyponatremia (false low sodium due to high protein) should be distinguished from true hyponatremia to avoid inappropriate fluid management.
- Hematoma Formation (SC Use in ITP): Gamunex-C is not approved for subcutaneous use in patients with ITP because of the risk of hematoma formation.
Gamunex-C, like other immune globulin products, can interact with certain medications and affect laboratory tests:
- Live Virus Vaccines: The antibodies in Gamunex-C can interfere with the immune response to live attenuated virus vaccines (e.g., Measles, Mumps, Rubella [MMR], Varicella [chickenpox], Yellow Fever). Vaccination with such vaccines should generally be deferred for at least 6 months (and up to 11 months depending on the vaccine and Gamunex-C dose) after Gamunex-C administration. Always consult the prescribing information and your healthcare provider for specific vaccination recommendations.
- Nephrotoxic Drugs: Concomitant use with other medications known to cause kidney damage (nephrotoxic drugs) may increase the risk of acute kidney injury. Examples include certain antibiotics (e.g., aminoglycosides) or loop diuretics. Close monitoring of renal function is recommended when these drugs are co-administered.
- Interference with Laboratory Tests: Passively transferred antibodies from Gamunex-C can lead to false-positive serological test results (e.g., for certain viral infections like HIV, Hepatitis C) or interfere with specific assay readings, such as blood group antibody testing (Coombs’ test) or blood glucose readings (if the testing system uses glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) methods, though Gamunex-C does not contain sugar, which typically causes this interference in other products). These effects can persist for several months after the last infusion.
- Heparin: Avoid simultaneous administration of Gamunex-C and Heparin through a single lumen delivery device due to incompatibilities. The infusion line should be flushed with 5% Dextrose in Water (D5W) or 0.9% Sodium Chloride for Injection, and not with Heparin.
Patients should always inform their healthcare provider about all prescription medications, over-the-counter drugs, herbal remedies, and supplements they are taking to avoid potential interactions.
The dosage of Gamunex-C is highly individualized based on the specific indication, patient body weight, clinical response, and, for some conditions, targeted serum IgG trough levels.
- Intravenous (IV) Dosage:
- Primary Humoral Immunodeficiency (PIDD):
- Dose: Typically 300 to 600 mg/kg (0.3 to 0.6 g/kg) body weight, administered every 3 to 4 weeks.
- Adjustment: Dosage and frequency are adjusted based on the patient’s clinical response (e.g., reduction in infection rate) and to achieve desired IgG trough serum levels (often aiming for trough levels typically above 500-800 mg/dL).
- Infusion Rate: Initial rate usually 1 mg/kg/min (0.01 mL/kg/min). If the infusion is well-tolerated, the rate may be gradually increased to a maximum of 8 mg/kg/min (0.08 mL/kg/min). For patients at risk for renal dysfunction or thrombosis, administer at the minimum infusion rate practicable.
- Idiopathic Thrombocytopenic Purpura (ITP):
- Dose: 2 g/kg (20 mL/kg) body weight, administered as a single dose. The total dose may be divided into two 1 g/kg (10 mL/kg) doses given on 2 consecutive days. If an adequate increase in platelet count is observed after the first 1 g/kg dose, the second dose may be withheld.
- Infusion Rate: Initial rate 1 mg/kg/min, gradually increased to a maximum of 8 mg/kg/min if tolerated.
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP):
- Loading Dose: 2 g/kg (20 mL/kg) total dose, given in divided doses over 2 to 4 consecutive days.
- Maintenance Dose: 1 g/kg (10 mL/kg) every 3 weeks, given over 1 day or divided into two doses of 0.5 g/kg (5 mL/kg) given on 2 consecutive days.
- Infusion Rate: Initial rate 2 mg/kg/min (0.02 mL/kg/min), gradually increased to a maximum of 8 mg/kg/min (0.08 mL/kg/min) if tolerated.
- Subcutaneous (SC) Dosage (for PIDD only):
- Initial Weekly Dose (Conversion from IV): The initial weekly SC dose is calculated to achieve a systemic serum IgG exposure not inferior to that of the previous IVIG treatment. A common conversion factor is to multiply the previous total monthly IV dose (in grams) by 1.37, and then divide by the number of weeks in the prior IV dosing interval (e.g., 3 or 4 weeks).
- Maintenance Dose: Adjusted based on the patient’s clinical response and serum IgG trough levels.
- Frequency: Typically administered weekly.
- Infusion Rate/Volume per Site:
- Adults: Up to 8 infusion sites simultaneously; typical rate is 20-30 mL/hour per site; typical volume per site can be up to 30 mL.
- Pediatric patients: Up to 6 infusion sites simultaneously; typical rate is 10-20 mL/hour per site depending on weight; typical volume per site up to 20-30 mL.
- Ensure infusion sites are at least 2 inches (5 cm) apart and rotated with each infusion.
Gamunex-C is a prescription-only medication (POM). It is a highly specialized biological product requiring strict medical oversight.
- Specialist Prescribing: Gamunex-C must be prescribed by a licensed healthcare professional, typically an immunologist, neurologist, or hematologist, who has expertise in the diagnosis and management of the specific conditions for which it is indicated.
- Confirmed Diagnosis: A definitive medical diagnosis of Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura, or Chronic
